BioNTech Results Presentation Deck

Two bispecific antibodies partnered with Genmab ● ● 3 Next-Gen checkpoint immunomodulators ● 50:50 profit/loss share Both programs in the clinic Potential "first-in-class" bispecific antibodies Designed to address 10 resistance mechanisms 14 Checkpoint Blockade PD-L1 BNT311 Costimulus on T and NK cells Product Candidate BNT311 (GEN1046) BNT312 (GEN1042) 4-1BB Preclinical Costimulus on tumor stroma CD-40 BNT312 PD-L1x4-1BB CD-40x4-1BB Phase 1 Ph1/2a Ph1/2a Costimulus on T and NK cells 4-1BB Phase 2 Data update 2H 2020 BIONTECH

View entire presentation